PTGX
Protagonist Therapeutics, Inc
NASDAQ · Healthcare · Biotechnology · US
$143.00
−0.49%Sep 11, 2026, 01:45 UTC
Protagonist Therapeutics President and CEO Dinesh V. Patel sold 124,000 shares of the company's common stock for approximately $18.2 million between September 8 and September 10, 2026, under a pre-arranged 10b5-1 trading plan.
Source:Sep 8, 2026, 20:05 UTC
Protagonist Therapeutics announced a share repurchase program authorizing up to $300 million of its common stock, funded from cash and collaboration payments.
Source:Aug 28, 2026, 21:39 UTC
The U.S. Food and Drug Administration approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, announced on Friday.
Aug 5, 2026, 22:26 UTC
Protagonist Therapeutics reported Q2 2026 earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.11 per share, compared to a loss of $0.55 per share a year ago.
Source: